#1
|
||||
|
||||
Ibuprofen reduce the preventive effects of ASA
DG ALERT: The FDA warned that the concomitant use of ibuprofen could reduce the cardioprotective and stroke preventive effects of low-dose aspirin.
More soon on [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] in the next Doctor's Guide Weekly Edition. |
#2
|
||||
|
||||
Öèòàòà:
|
#3
|
||||
|
||||
À ÷åì ýòî îáúÿñíÿþò? Òåì, ÷òî èáóïðîôåí ñëàáåå èíãèáèðóåò ÖÎÃ?
|
#4
|
||||
|
||||
Êðîìå òîãî, îí åùå è îñëàáëÿåò äåéñòâèå èáóïðîôåíà ñ óâåëè÷åíèåì ïîáî÷íûõ ýôôåêòîâ
|
#5
|
||||
|
||||
ß íå ïîíÿë, àñïèðèí òîæå îñëàáëÿåò äåéñòâèå èáóïðîôåíà?
|
#6
|
||||
|
||||
Öèòàòà:
|
#7
|
||||
|
||||
Óäèâèòåëüíàÿ èñòîðèÿ... êóäà òàì îñëàáëÿòü-òî?
|
#8
|
||||
|
||||
Íó è øóò ñ íèì, ñ èáóïðîôåíîì. Ñêîëüêî åãî ïàöèåíòîâ ïîëó÷àåò íà ïîñòîÿííîé îñíîâå?
|
#9
|
||||
|
||||
Íàñêîëüêî ÿ ïîíÿë, çà ðóáåæîì ýòî - äîâîëüíî ïîïóëÿðíûé ïðåïàðàò ïðè îñòåîàðòðîçå. Òàì ñòóïåí÷àòàÿ òåðàïèÿ - íà÷èíàþò ñî ñëàáûõ ïðåïàðàòîâ, è ìíîãèì ïîæèëûì áîëüíûì õâàòàåò (èì áû è ïëàöåáî õâàòèëî, íàâåðíîå). Âîò è âîçíèêëà ïðîáëåìà - ñ îäíîé ñòîðîíû, èáóïðîôåí ïðîòèâ îñòåîàðòðîçà è ò.ï. ñóñòàâíûõ áîëåé è áîëåé â ñïèíå, ñ äðóãîé ñòîðîíû - àñïèðèí äëÿ ñíèæåíèÿ ðèñêà êàðäèîëîãè÷åñêèõ îñëîæíåíèé...
Ó íàñ â áîëüøèíñòâå ñëó÷àåâ (íàñêîëüêî ÿ ïîíèìàþ) ïðè îñòåîàðòðîçå íàçíà÷àþò äèêëîôåíàê. À àñïèðèí äëÿ ïðîôèëàêòèêè êàðä. îñëîæíåíèé íàçíà÷àþò òîëüêî íåñêîëüêèì áîëüíûì â Ìîñêâå. Òàê ÷òî, ýòà ïðîáëåìà, äåéñòâèòåëüíî, íîñèò äîâîëüíî àáñòðàêòíûé õàðàêòåð. |
#10
|
||||
|
||||
Äëÿ áîëåå ïûòëèâûõ ÷èòàòåëåé åñòü ïîäðîáíåéøèé ðàçáîð ïóáëèêàöèé ïî òåìå â ñòàòüå:
MacDonald TM, Wei L. Is there an interaction between the cardiovascular protective effects of low-dose aspirin and ibuprofen? Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):275-80. Êðîìå âûøåóêàçàííîãî òðåíäà, íåêîòîðûå äðóãèå: In a recent meta-analysis of 120 randomised trials of cyclooxygenase 2, selective drugs versus placebo cyclooxygenase 2 drugs significantly increased the rate of myocardial infarction by 86% after adjustment (113 myocardial infarctions in 18,496 patients taking cyclooxygenase 2s versus 56 myocardial infarctions out of 17,901 taking placebo) and vascular events by 41% (61 events in 18,552 subjects taking cyclooxygenase 2s versus 39 out of 17,933 subjects taking placebo (Baigent, personal communication). However, an analysis that compared cyclooxygenase 2 drugs with traditional NSAIDs (excluding naproxen) found no difference in myocardial infarction or vascular event rates (Baigent, personal communication). Interestingly, naproxen fared rather well against the cyclooxygenase 2 having 104% less myocardial infarctions after adjustment (99 myocardial infarctions in 16,373 patients taking cyclooxygenase 2s versus 56 myocardial infarctions out of 16,543 taking Naproxen) and 57% less vascular events (186 events per 16,368 patients taking cyclooxygenase 2s and 141 out of 16,542 patients taking naproxen). There have been few trials of traditional NSAIDs versus placebo and there are almost no randomised trial data to support this contention although the ADAPT trial was stopped due to safety concerns about both celecoxib and naproxen and further analyses of another trial involving prophylactic aspirin suggested a dose-related increased cardiovascular event with aspirin compared to placebo in patients at presumed low cardiovascular risk (Baron et al. 2003). Thus, whilst no meta-analysis has been done of traditional NSAIDs versus placebo, the inference is that these NSAIDs increase cardiovascular disease. Ïîõîæå, ÷òî íàèáîëåå áåçîïàñíûé â êàðäèîëîãè÷åñêîì ïëàíå - ýòî íàïðîêñåí, õîòÿ Òîïîëü Ý. è ñîàâò. ýòîãî íå îáíàðóæèëè: Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med. 2006 Jul;119(7):552-9.
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |